IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

MaxCyte Inc - Maryland-based cell and gene therapies firm - Announces GBP40 million subscription ...

Alliance News 3 February, 2021 | 9:38PM
Email Form Facebook Twitter LinkedIn RSS

MaxCyte Inc - Maryland-based cell and gene therapies firm - Announces GBP40 million subscription via private placement of 5.7 million shares at 700 pence each, a 4.5% premium to the company's mid-market Tuesday closing price. Subscribers include new investors D1 Capital Partners, T Rowe Price, ArrowMark Partners, Baron Capital Group and First Light Asset Management plus existing investors Casdin Capital and Sofinnova Partners. Says subscription provides "strategic capitalisation round" introducing crossover investors as MaxCyte progresses its 2021 Nasdaq dual listing, which is still on track.

"Proceeds from the subscription will be used to strengthen MaxCyte's balance sheet to enable the company to support the burgeoning field of next-generation cell therapeutic development via its best-in-class cell engineering approaches," says MaxCyte.

Stifel Nicolaus Europe Ltd, MaxCyte's newly appointed joint corporate broker - alongside Panmure Gordon and Numis - acts as sole private placement agent for the subscription.

Current stock price: 670.00 pence

Year-to-date change: up 27%

By Anna Farley; annafarley@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
MaxCyte Inc 295.00 GBX -3.28 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures